S&P Capital IQ Initiates Coverage on TONIX Pharmaceuticals Holding Corp. in Standard & Poor’s Factual Stock Reports

NEW YORK--()--S&P Capital IQ announced today that it has commenced Standard & Poor’s Factual Stock Report coverage on TONIX Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) develops prescription medications for challenging disorders of the central nervous system ("CNS"). The company targets conditions characterized by significant unmet medical needs, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. Tonix's core technology improves the quality of sleep in patients with chronic pain syndromes.

TNXP is focused on developing new pharmaceutical products for CNS conditions that may be safer and more effective than currently available treatments. Tonix uses ongoing advances in science and medicine to search for potential therapeutic solutions among already existing prescription pharmaceutical agents that have been successfully used in patients for other conditions. The company creates new dose formulations for these agents with the intent to developing products that are optimized for the new therapeutic uses or indications that Tonix targets.

TNXP's most advanced product candidate, sublingual TNX-102 ("TNX-102 SL") for FM and post-traumatic stress disorder ("PTSD"), is a novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. In 2013, TNX-102 SL is expected to enter Phase 3 for FM and Phase 2 for PTSD. The company is working to optimize the dose and formulation of TNX-102 to treat FM safely.

Tonix Pharmaceuticals Holding Corp. was founded in 2007.

Standard & Poor’s Factual Stock Report coverage on TONIX Pharmaceuticals Holdings Corp. will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit http://www.tonixpharma.com/ for additional information.

About Standard & Poor's Factual Stock Reports

Currently profiling approximately 500 issuers, Standard & Poor’s Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor’s Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor’s Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a business line of The McGraw-Hill Companies (NYSE:MHP), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today’s investors need. For more information visit www.spcapitaliq.com.

Contacts

TONIX Pharmaceuticals Holding Corp
Leland J. Gershell, 212-980-9155, ext. 104
leland.gershell@tonixpharma.com
or
S&P Capital IQ
Customers
Richard Albanese, 212-438-3647
richard_albanese@spcapitaliq.com
or
Media Relations
Michael Privitera, 212-438-6679
michael_Privitera@spcapitaliq.com

Sharing

Contacts

TONIX Pharmaceuticals Holding Corp
Leland J. Gershell, 212-980-9155, ext. 104
leland.gershell@tonixpharma.com
or
S&P Capital IQ
Customers
Richard Albanese, 212-438-3647
richard_albanese@spcapitaliq.com
or
Media Relations
Michael Privitera, 212-438-6679
michael_Privitera@spcapitaliq.com